Clinical Trial Update: HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) [Phase 2]

View source ↗

Summary

A Phase 2 HOPE-Duchenne trial evaluating CAP-1002 for Duchenne Muscular Dystrophy–related cardiomyopathy has completed and results were posted in January 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Duchenne Muscular Dystrophy

Drugs mentioned

• CAP-1002 (cardiosphere-derived cells)

Snippet

Sponsor: Capricor Inc. | Conditions: Duchenne Muscular Dystrophy, Cardiomyopathy | Phase 2 | Status: COMPLETED | Results posted: 2025-01-09